Patents by Inventor Keith E. Dionne
Keith E. Dionne has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20010027311Abstract: Osmotic delivery system semipermeable body assemblies that control the delivery rate of a beneficial agent from an osmotic delivery system incorporating one of the semipermeable body assemblies. A semipermeable body assembly or plug includes a semipermeable body which is positionable in an opening of an osmotic delivery system. The semipermeable body has a hollow interior portion having a size selected to obtain a predetermined liquid permeation rate through the semipermeable body. Because the beneficial agent in the osmotic delivery system is delivered at substantially the same rate the osmotic agent imbibes liquid which has permeated through the plug from a surrounding environment, the liquid permeation rate through the plug controls the delivery rate of the beneficial agent from the osmotic delivery system.Type: ApplicationFiled: May 18, 2001Publication date: October 4, 2001Inventors: Guohua Chen, Scott D. Lautenbach, Keith E. Dionne, Scott D. Jordan, Steve A. Berry, Craig I. Rodenberger, Rupal Ayer
-
Patent number: 6287295Abstract: Osmotic delivery system semipermeable body assemblies that control the delivery rate of a beneficial agent from an osmotic delivery system incorporating one of the semipermeable body assemblies. A semipermeable body assembly or plug includes a semipermeable body which is positionable in an opening of an osmotic delivery system. The semipermeable body has a hollow interior portion having a size selected to obtain a predetermined liquid permeation rate through the semipermeable body. Because the beneficial agent in the osmotic delivery system is delivered at substantially the same rate the osmotic agent imbibes liquid which has permeated through the plug from a surrounding environment, the liquid permeation rate through the plug controls the delivery rate of the beneficial agent from the osmotic delivery system.Type: GrantFiled: July 24, 1998Date of Patent: September 11, 2001Assignee: Alza CorporationInventors: Guohua Chen, Scott D. Lautenbach, Keith E. Dionne, Scott D. Jordan, Steve A. Berry, Craig I. Rodenberger, Rupal Ayer
-
Patent number: 6261584Abstract: The invention is directed to a device for delivering an active agent formulation for a predetermined administration period. An impermeable reservoir is divided into a water-swellable agent chamber and an active agent formulation chamber. Fluid from the environment is imbibed through a semipermeable plug into the water-swellable agent chamber and the active agent formulation is released through a back-diffusion regulating outlet. Delivery periods of up to 2 years are achieved.Type: GrantFiled: August 4, 1999Date of Patent: July 17, 2001Assignee: Alza CorporationInventors: John R. Peery, Keith E. Dionne, James B. Eckenhoff, Felix A. Landrau, Scott D. Lautenbach, Judy A. Magruder, Jeremy C. Wright
-
Patent number: 6217906Abstract: A delivery device having a first chamber containing an osmotic agent, a membrane forming a wall of the first chamber through which fluid is imbibed by osmosis, a second chamber containing a beneficial agent to be delivered, and a moveable piston separating the two chambers. In fluid communication with the second chamber is an orifice which comprises a slit valve. In the presence of pressure, the beneficial agent pushes through the slit, opening up a channel for delivery of the beneficial agent and creating flow. Because the slit remains closed in the absence of flow (or when the pressure is below the pressure required to open the slit), back diffusion of external fluids is eliminated when the slit is closed, which prevents contamination of the beneficial agent in the second chamber by external fluids. In addition, forward diffusion of the beneficial agent out of the capsule is prevented when the slit is closed.Type: GrantFiled: September 17, 1999Date of Patent: April 17, 2001Assignee: ALZA CorporationInventors: Juan C. Gumucio, Keith E. Dionne, James E. Brown
-
Patent number: 6156331Abstract: The invention is directed to a device for delivering an active agent formulation for a predetermined administration period. An impermeable reservoir is divided into a water-swellable agent chamber and an active agent formulation chamber. Fluid from the environment is imbibed through a semipermeable plug into the water-swellable agent chamber and the active agent formulation is released through a back-diffusion regulating outlet. Delivery periods of up to 2 years are achieved.Type: GrantFiled: May 12, 1999Date of Patent: December 5, 2000Assignee: ALZA CorporationInventors: John R. Peery, Keith E. Dionne, James B. Eckenhoff, deceased, Felix A. Landrau, Scott D. Lautenbach, Judy A Magruder, Jeremy C. Wright
-
Patent number: 6132420Abstract: The present invention relates to an osmotically driven agent delivery system for delivering a beneficial agent. The osmotic delivery system includes an osmotic agent which operates by imbibing fluid from an outside environment, causing the release of a beneficial agent. The osmotic delivery system includes a liquid or gel additive surrounding the osmotic agent for enhancing start-up and lubricating the osmotic agent. The liquid or gel additive is an incompressible lubricating fluid which fills any air gaps between the osmotic agent and the walls of a chamber and substantially reduces start-up delays.Type: GrantFiled: November 14, 1997Date of Patent: October 17, 2000Assignee: Alza CorporationInventors: Keith E. Dionne, Scott D. Lautenbach
-
Patent number: 6123700Abstract: A sealed, implantable, encapsulation device (20) for diffusing a biologically active product or function to an individual which includes a substantially non-porous fitting (32) including an inner surface (33) defining an access port (34). A permselective, porous, membrane (21), having an interior surface (22), cooperates with the fitting inner surface (33) to form a storage cavity (23) therebetween. The membrane interior surface (22) is in substantially cell-tight dry sealing engagement with fitting (32) to seal cavity (23). Living cells (24) are disposed in the cavity (23) which are capable of secreting the biologically active product to an individual. The membrane (21) is of a material capable of permitting the passage of substances between the individual and cells required to provide the biological product or function. A plug member (35) is positioned in the access port (34) and seated in cell-tight sealing engagement with the fitting inner surface (33).Type: GrantFiled: January 30, 1998Date of Patent: September 26, 2000Assignee: Brown University Research FoundationInventors: John F. Mills, Edward J. Doherty, Tyrone F. Hazlett, Keith E. Dionne, Nicholas F. Warner, Brian M. Cain, David H. Rein
-
Patent number: 6083523Abstract: An immunoisolatory vehicle for the implantation into an individual of cells which produce a needed product or provide a needed metabolic function. The vehicle is comprised of a core region containing isolated cells and materials sufficient to maintain the cells, and a permselective, biocompatible, peripheral region free of the isolated cells, which immunoisolates the core yet provides for the delivery of the secreted product or metabolic function to the individual.Type: GrantFiled: September 4, 1998Date of Patent: July 4, 2000Assignees: Brown University Research Foundation, Brown UniversityInventors: Keith E. Dionne, Dwaine F. Emerich, Diane Hoffman, Paul R. Sanberg, Lisa Christenson, Orion D. Hegre, David W. Scharp, Paul E. Lacy, Patrick Aebischer, Alfred V. Vasconcellos, Michael J. Lysaght, Frank T. Gentile
-
Patent number: 5997527Abstract: A delivery device having a first chamber containing an osmotic agent, a membrane forming a wall of the first chamber through which fluid is imbibed by osmosis, a second chamber containing a beneficial agent to be delivered, and a moveable piston separating the two chambers. In fluid communication with the second chamber is an orifice which comprises a slit valve. In the presence of pressure, the beneficial agent pushes through the slit, opening up a channel for delivery of the beneficial agent and creating flow. Because the slit remains closed in the absence of flow (or when the pressure is below the pressure required to open the slit), back diffusion of external fluids is eliminated when the slit is closed, which prevents contamination of the beneficial agent in the second chamber by external fluids. In addition, forward diffusion of the beneficial agent out of the capsule is prevented when the slit is closed.Type: GrantFiled: March 23, 1998Date of Patent: December 7, 1999Assignee: ALZA CorporationInventors: Juan C. Gumucio, Keith E. Dionne, James E. Brown
-
Patent number: 5985305Abstract: The invention is directed to a device for delivering an active agent formulation for a predetermined administration period. An impermeable reservoir is divided into a water-swellable agent chamber and an active agent formulation chamber. Fluid from the environment is imbibed through a semipermeable plug into the water-swellable agent chamber and the active agent formulation is released through a back-diffusion regulating outlet. Delivery periods of up to 2 years are achieved.Type: GrantFiled: October 2, 1997Date of Patent: November 16, 1999Assignee: Alza CorporationInventors: John R. Peery, Keith E. Dionne, James B. Eckenhoff, Felix A. Landrau, Scott D. Lautenbach, Judy A. Magruder, Jeremy C. Wright
-
Patent number: 5972369Abstract: A sustained release delivery system for delivering a beneficial agent is provided. The system includes a reservoir comprising the beneficial agent and a capillary channel in communication with the reservoir and the exterior of the system for delivering the beneficial agent from the system. The capillary channel has a cross-sectional area and a length selected to deliver the beneficial agent at a predetermined rate. The system may further include an outer surface that is impermeable and non-porous during delivery of the beneficial agent. The beneficial agent may be formulated in a glassy sugar matrix.Type: GrantFiled: March 30, 1998Date of Patent: October 26, 1999Assignee: ALZA CorporationInventors: Wouter E. Roorda, Keith E. Dionne, James E. Brown, Jeremy C. Wright, Craig R. Davis, Steven J. Prestrelski, Stelios T. Tzannis
-
Method and apparatus for sealing implantable, membrane encapsulation devices containing living cells
Patent number: 5932460Abstract: A sealed, implantable, encapsulation device (20) for diffusing a biologically active product or function to an individual which includes a substantially non-porous fitting (32) including an inner surface (33) defining an access port (34). A permselective, porous, membrane (21), having an interior surface (22), cooperates with the fitting inner surface (33) to form a storage cavity (23) therebetween. The membrane interior surface (22) is in substantially cell-tight dry sealing engagement with fitting (32) to seal cavity (23). Living cells (24) are disposed in the cavity (23) which are capable of secreting the biologically active product to an individual. The membrane (21) is of a material capable of permitting the passage of substances between the individual and cells required to provide the biological product or function. A plug member (35) is positioned in the access port (34) and seated in cell-tight sealing engagement with the fitting inner surface (33).Type: GrantFiled: June 6, 1995Date of Patent: August 3, 1999Assignee: Brown University Research FoundationInventors: John F. Mills, Edward J. Doherty, Tyrone F. Hazlett, Keith E. Dionne, Nicholas F. Warner, Brian M. Cain, David H. Rein -
Patent number: 5916554Abstract: A biocompatable and biostable flexible pouch for use e.g., in implanting cell bodies producing therapeutic agents, featuring, in various aspects, either encapsulated or unencapsulated cell bodies contained within the pouch; and a means for attaching the opening of the pouch to a vascularized tissue pedicle.Type: GrantFiled: June 5, 1995Date of Patent: June 29, 1999Assignee: Washington UniversityInventors: Keith E. Dionne, David W. Scharp
-
Patent number: 5874099Abstract: A method of forming an implantable and retrievable immunoisolatory vehicles is disclosed, the method comprising the steps of first forming a core comprising a volume of at least 1 .mu.l and at least 10.sup.4 cells capable of providing a biologically active product or metabolic or immunologic function, said cells being dispersed in a biocompatible hydrogel or extracellular matrix, and then forming around the core a surrounding external biocompatible thermoplastic or hydrogel jacket free of said cells projecting externally thereof, said jacket having molecular weight cutoff permitting passage of molecules to and from the core through said jacket to provide said biologically active product or function.Type: GrantFiled: May 24, 1995Date of Patent: February 23, 1999Assignee: Brown University Research FoundationInventors: Keith E. Dionne, Dwaine F. Emerich, Diane Hoffman, Paul R. Sanberg, Lisa Christenson, Orion D. Hegre, David W. Scharp, Paul E. Lacy, Patrick Aebischer, Alfred V. Vasoohcellos, Michael J. Lysaght, Frank T. Gentile
-
Patent number: 5871767Abstract: A method for treatment of a neurodegenerative condition in a patient comprising implanting in the patient at least one immunoisolatory vehicle comprising a corc comprising a volume of at least 1 .mu.l and at least 10.sup.4 living cells which secrete at least one biologically active product, said cells being dispersed in a biocompatible matrix comprising a hydrogel or extracellular matrix components, and an external jacket surrounding the core, the jacket comprising a biocompatible hydrogel or thermoplastic, the jacket being free of cells projecting externally thereof, said jacket having a molecular weight cutoff permitting the passage of the biologically active product from the core through the jacket.Type: GrantFiled: May 24, 1995Date of Patent: February 16, 1999Assignee: Brown University Research FoundationInventors: Keith E. Dionne, Dwaine F. Emerich, Diane Hoffman, Paul R. Sanberg, Lisa Christenson, Orion D. Hegre, David W. Scharp, Paul E. Lacy, Patrick Aebischer, Alfred V. Vasconcellos, Michael J. Lysaght, Frank T. Gentile
-
Patent number: 5869077Abstract: A method for treating diabetes in a patient comprising subcutaneously implanting in the patient at least one immunoisolatory vehicle comprising a core comprising a volume of at least 1 .mu.l and at least about 10.sup.4 living cells which secrete insulin, said cells being dispersed in a biocompatible matrix comprising a hydrogel or extracellular matrix components, and a surrounding external jacket of a biocompatible thermoplastic or hydrogel free of said cells projecting externally thereof, said jacket being permselective and immunoisolatory, said jacket having a molecular weight cutoff permitting passage of molecules between the patient and core through said jacket wherein the insulin is released from the immunoisolatory vehicle into the patient's body to treat diabetes.Type: GrantFiled: May 24, 1995Date of Patent: February 9, 1999Assignee: Brown University Research FoundationInventors: Keith E. Dionne, Dwaine F. Emerich, Diane Hoffman, Paul R. Sanberg, Lisa Christenson, Orion D. Hegre, David W. Scharp, Paul E. Lacy, Patrick Aebischer, Alfred V. Vasconcellos, Michael J. Lysaght, Frank T. Gentile
-
Patent number: 5834001Abstract: A method of forming an implantable and retrievable immunoisolatory vehicle is disclosed, the method comprising the steps of first forming a jacket of biocompatible thermoplastic or hydrogel, and then loading the jacket with a core comprising a volume of at least 1 .mu.l and at least 10.sup.4 cells capable of secreting a biocompatible matrix comprising a hydrogel or extracellular matrix, said jacket having a molecular weight cutoff permitting passage of molecules thereacross to provide said biologically active product or said function.Type: GrantFiled: May 24, 1995Date of Patent: November 10, 1998Assignee: Brown University Research FoundationInventors: Keith E. Dionne, Dwaine F. Emerich, Diane Hoffman, Paul R. Sanberg, Lisa Christenson, Orion D. Hegre, David W. Sharp, Paul E. Lacy, Patrick Aebischer, Alfred V. Vasconcellos, Michael J. Lysaght, Frank T. Gentile
-
Patent number: 5800828Abstract: Immunoisolatory vehicles having a core and a surrounding jacket are disclosed, the core having a volume in excess of 1 .mu.l and at least about 10.sup.4 living cells capable of secreting a biologically active product or of providing a biological function to a patient, the cells dispersed in a biocompatible matrix formed of a hydrogel or an extracellular matrix component, and the external jacket being permselective, biocompatible and having a molecular weight cutoff permitting passage of molecules between the patient and the core through said jacket to provide said biological product or function.Type: GrantFiled: January 10, 1994Date of Patent: September 1, 1998Assignee: Brown University Research FoundationInventors: Keith E. Dionne, Dwaine F. Emerich, Diane Hoffman, Paul R. Sanberg, Lisa Christenson, Orion D. Hegre, David W. Scharp, Paul E. Lacy, Patrick Aebischer, Alfred V. Vasconcellos, Michael J. Lysaght, Frank T. Gentile
-
Patent number: 5800829Abstract: A method of making an immunoisolatory vehicle comprised of a core comprising living cells dispersed in a biocompatible matrix is disclosed, the cells being capable of secreting a biologically active product or of providing a metabolic or immunologic function to an individual, and an external jacket surrounding said core which is a biocompatible, permselective thermoplastic or hydrogel, said jacket being free of said cells, comprising coextruding a suspension comprising said cells dispersed in a precursor matrix material comprising extracellular matrix components or a biocompatible hydrogel precursor, and a solution of a biocompatible jacket precursor from a nested dual-bore extrusion nozzle, wherein the suspension of (a) is coextruded from the inner bore and the solution of (b) is coextruded from the outer bore of the nozzle, to form said jacket as the solution of (b) and the suspension of (a) arc coextruded; and exposing the vehicle to a treatment that forms a core comprising a volume of at least 1 .mu.Type: GrantFiled: May 24, 1995Date of Patent: September 1, 1998Assignee: Brown University Research FoundationInventors: Keith E. Dionne, Dwaine F. Emerich, Diane Hoffman, Paul R. Sanberg, Lisa Christenson, Orion D. Hegre, David W. Scharp, Paul E. Lacy, Patrick Aebischer, Alfred V. Vasconcellos, Michael J. Lysaght, Frank T. Gentile
-
Patent number: 5798113Abstract: A method of providing a biologically active molecule or metabolic or immunologic function to a patient, comprising implanting into the body of the patient at least one immunoisolatory vehicle comprising a core comprising a volume in excess of 1 .mu.l and at least about 10.sup.4 living cells dispersed in a biocompatible matrix formed of a hydrogel or extracellular matrix components, said cells being capable of secreting a biologically active product or of providing a metabolic or immunologic function to the patient; and an external jacket surrounding said core, said jacket being formed from a thermoplastic or hydrogel, said jacket being free of said cells projecting externally therefrom, said jacket being biocompatible and having a molecular weight cutoff permitting passage of molecules between the patient and the core through said jacket to provide said biologically active product of function.Type: GrantFiled: May 24, 1995Date of Patent: August 25, 1998Assignee: Brown University Research FoundationInventors: Keith E. Dionne, Dwaine F. Emerich, Diane Hoffman, Paul R. Sanberg, Lisa Christenson, Orion D. Hegre, David W. Scharp, Paul E. Lacy, Patrick Aebischer, Alfred V. Vasooncellos, Michael J. Lysaght, Frank T. Gentile